8-K 1 a07-16834_18k.htm 8-K

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported)  June 18, 2007

Cephalon, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

0-19119

23-2484489

(State or Other Jurisdiction

(Commission

(IRS Employer

of Incorporation)

File Number)

Identification No.)

 

 

 

41 Moores Road

 

 

Frazer, Pennsylvania

 

19355

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code  (610) 344-0200

Not Applicable

 

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 



Item 8.01               Other Events.

On June 18, 2007, Cephalon, Inc. (the “Company”) issued a press release regarding the United States Food and Drug Administration’s approval to market NUVIGIL™ (armodafinil) Tablets [C-IV] for the treatment of excessive sleepiness associated with obstructive sleep apnea/hypopnea, narcolepsy and shift work sleep disorder.  The Company hereby incorporates by reference the press release dated June 18, 2007, attached hereto as Exhibit 99.1, and made a part of this Item 8.01.

Item 9.01               Financial Statements and Exhibits.

(d)               Exhibits.

Exhibit No.

 

Description of Exhibit

 

 

 

99.1

 

Press Release dated June 18, 2007

 

2



SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CEPHALON, INC.

 

 

 

 

Date: June 18, 2007

By:

/s/ J. Kevin Buchi

 

 

 

 

J. Kevin Buchi

 

 

Executive Vice President and Chief Financial
Officer

 

3



EXHIBIT INDEX

Exhibit No.

 

Description of Exhibit

 

 

 

99.1

 

Press Release dated June 18, 2007

 

4